Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
Running, not enrolling · Phase 2 · Has a placebo group
Conditions studied: Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
In brief
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Key facts
- Study ID
- NCT04838301
- Run by
- University of Arizona
- People needed
- 100
- Starts
- 2023-08-15
- Expected to finish
- 2027-03-18
- Last updated by the study team
- 2026-06-30
Who can join
Age: 55 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Perseverance Research Center — Scottsdale, Arizona, United States
- University of Arizona / Clinical & Translational Sciences Research Center — Tucson, Arizona, United States
- ATP Clinical Research — Costa Mesa, California, United States
- Syrentis Clinical Research — Santa Ana, California, United States
- Optimus U Corporation — Miami, Florida, United States
- Miami Jewish Health — Miami, Florida, United States
- Combined Research Orlando — Orlando, Florida, United States
- Conquest Research — Winter Park, Florida, United States
- MedVadis Research — Waltham, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.